Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Oncogenic Kras induces Nix-mediated mitophagy to promote pancreatic cancer.

Humpton TJ, Alagesan B, DeNicola GM, Lu D, Yordanov GN, Leonhardt CS, Yao MA, Alagesan P, Zaatari MN, Park Y, Skepper JN, Macleod KF, Perez-Mancera PA, Murphy MP, Evan GI, Vousden KH, Tuveson DA.

Cancer Discov. 2019 Jul 1. pii: CD-18-1409. doi: 10.1158/2159-8290.CD-18-1409. [Epub ahead of print]

PMID:
31263025
2.

BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma.

Lazarus KA, Hadi F, Zambon E, Bach K, Santolla MF, Watson JK, Correia LL, Das M, Ugur R, Pensa S, Becker L, Campos LS, Ladds G, Liu P, Evan GI, McCaughan FM, Le Quesne J, Lee JH, Calado D, Khaled WT.

Nat Commun. 2018 Aug 20;9(1):3327. doi: 10.1038/s41467-018-05790-5.

3.

Myc Cooperates with Ras by Programming Inflammation and Immune Suppression.

Kortlever RM, Sodir NM, Wilson CH, Burkhart DL, Pellegrinet L, Brown Swigart L, Littlewood TD, Evan GI.

Cell. 2017 Nov 30;171(6):1301-1315.e14. doi: 10.1016/j.cell.2017.11.013.

4.

Determination of the physiological and pathological roles of E2F3 in adult tissues.

Gamper I, Burkhart DL, Bywater MJ, Garcia D, Wilson CH, Kreuzaler PA, Arends MJ, Zheng YW, Perfetto A, Littlewood TD, Evan GI.

Sci Rep. 2017 Aug 30;7(1):9932. doi: 10.1038/s41598-017-09494-6.

5.

Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked.

Evan GI, Hah N, Littlewood TD, Sodir NM, Campos T, Downes M, Evans RM.

Clin Cancer Res. 2017 Apr 1;23(7):1647-1655. doi: 10.1158/1078-0432.CCR-16-3275. Review.

6.

SOX2 Drives Bronchial Dysplasia in a Novel Organotypic Model of Early Human Squamous Lung Cancer.

Correia LL, Johnson JA, McErlean P, Bauer J, Farah H, Rassl DM, Rintoul RC, Sethi T, Lavender P, Rawlins EL, Littlewood TD, Evan GI, McCaughan FM.

Am J Respir Crit Care Med. 2017 Jun 1;195(11):1494-1508. doi: 10.1164/rccm.201510-2084OC.

7.

Myc Expression Drives Aberrant Lipid Metabolism in Lung Cancer.

Hall Z, Ament Z, Wilson CH, Burkhart DL, Ashmore T, Koulman A, Littlewood T, Evan GI, Griffin JL.

Cancer Res. 2016 Aug 15;76(16):4608-18. doi: 10.1158/0008-5472.CAN-15-3403. Epub 2016 Jun 22.

8.

Identification of MYC-Dependent Transcriptional Programs in Oncogene-Addicted Liver Tumors.

Kress TR, Pellanda P, Pellegrinet L, Bianchi V, Nicoli P, Doni M, Recordati C, Bianchi S, Rotta L, Capra T, Ravà M, Verrecchia A, Radaelli E, Littlewood TD, Evan GI, Amati B.

Cancer Res. 2016 Jun 15;76(12):3463-72. doi: 10.1158/0008-5472.CAN-16-0316. Epub 2016 Apr 13.

9.

A MYC-Driven Change in Mitochondrial Dynamics Limits YAP/TAZ Function in Mammary Epithelial Cells and Breast Cancer.

von Eyss B, Jaenicke LA, Kortlever RM, Royla N, Wiese KE, Letschert S, McDuffus LA, Sauer M, Rosenwald A, Evan GI, Kempa S, Eilers M.

Cancer Cell. 2015 Dec 14;28(6):743-757. doi: 10.1016/j.ccell.2015.10.013.

10.

p53 Restoration in Induction and Maintenance of Senescence: Differential Effects in Premalignant and Malignant Tumor Cells.

Harajly M, Zalzali H, Nawaz Z, Ghayad SE, Ghamloush F, Basma H, Zainedin S, Rabeh W, Jabbour M, Tawil A, Badro DA, Evan GI, Saab R.

Mol Cell Biol. 2015 Nov 23;36(3):438-51. doi: 10.1128/MCB.00747-15. Print 2016 Feb 1.

11.

Sall2 is required for proapoptotic Noxa expression and genotoxic stress-induced apoptosis by doxorubicin.

Escobar D, Hepp MI, Farkas C, Campos T, Sodir NM, Morales M, Álvarez CI, Swigart L, Evan GI, Gutiérrez JL, Nishinakamura R, Castro AF, Pincheira R.

Cell Death Dis. 2015 Jul 16;6:e1816. doi: 10.1038/cddis.2015.165.

12.

Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.

Massó-Vallés D, Jauset T, Serrano E, Sodir NM, Pedersen K, Affara NI, Whitfield JR, Beaulieu ME, Evan GI, Elias L, Arribas J, Soucek L.

Cancer Res. 2015 Apr 15;75(8):1675-81. doi: 10.1158/0008-5472.CAN-14-2852.

13.

The estrogen receptor fusion system in mouse models: a reversible switch.

Whitfield J, Littlewood T, Evan GI, Soucek L.

Cold Spring Harb Protoc. 2015 Mar 2;2015(3):227-34. doi: 10.1101/pdb.top069815.

PMID:
25734072
14.

KSHV viral cyclin interferes with T-cell development and induces lymphoma through Cdk6 and Notch activation in vivo.

Pekkonen P, Järviluoma A, Zinovkina N, Cvrljevic A, Prakash S, Westermarck J, Evan GI, Cesarman E, Verschuren EW, Ojala PM.

Cell Cycle. 2014;13(23):3670-84. doi: 10.4161/15384101.2014.964118.

15.

BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues.

Muthalagu N, Junttila MR, Wiese KE, Wolf E, Morton J, Bauer B, Evan GI, Eilers M, Murphy DJ.

Cell Rep. 2014 Sep 11;8(5):1347-53. doi: 10.1016/j.celrep.2014.07.057. Epub 2014 Aug 28.

16.

CDK2 transcriptional repression is an essential effector in p53-dependent cellular senescence-implications for therapeutic intervention.

Zalzali H, Nasr B, Harajly M, Basma H, Ghamloush F, Ghayad S, Ghanem N, Evan GI, Saab R.

Mol Cancer Res. 2015 Jan;13(1):29-40. doi: 10.1158/1541-7786.MCR-14-0163. Epub 2014 Aug 22.

17.

Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis.

Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, Redondo-Campos S, Folch G, Gonzàlez-Juncà A, Sodir NM, Massó-Vallés D, Beaulieu ME, Swigart LB, Mc Gee MM, Somma MP, Nasi S, Seoane J, Evan GI, Soucek L.

Nat Commun. 2014 Aug 18;5:4632. doi: 10.1038/ncomms5632.

18.

The kinetics of ER fusion protein activation in vivo.

Wilson CH, Gamper I, Perfetto A, Auw J, Littlewood TD, Evan GI.

Oncogene. 2014 Oct 2;33(40):4877-80. doi: 10.1038/onc.2014.78. Epub 2014 Mar 24.

19.

A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis.

Olive V, Sabio E, Bennett MJ, De Jong CS, Biton A, McGann JC, Greaney SK, Sodir NM, Zhou AY, Balakrishnan A, Foth M, Luftig MA, Goga A, Speed TP, Xuan Z, Evan GI, Wan Y, Minella AC, He L.

Elife. 2013 Oct 15;2:e00822. doi: 10.7554/eLife.00822.

20.

Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.

Baek KH, Bhang D, Zaslavsky A, Wang LC, Vachani A, Kim CF, Albelda SM, Evan GI, Ryeom S.

J Clin Invest. 2013 Oct;123(10):4375-89. doi: 10.1172/JCI67465. Epub 2013 Sep 9.

21.

Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy.

Shchors K, Persson AI, Rostker F, Tihan T, Lyubynska N, Li N, Swigart LB, Berger MS, Hanahan D, Weiss WA, Evan GI.

Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):E1480-9. doi: 10.1073/pnas.1219142110. Epub 2013 Mar 29.

22.

Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.

Soucek L, Whitfield JR, Sodir NM, Massó-Vallés D, Serrano E, Karnezis AN, Swigart LB, Evan GI.

Genes Dev. 2013 Mar 1;27(5):504-13. doi: 10.1101/gad.205542.112.

23.

Sequential Cdk1 and Plk1 phosphorylation of protein tyrosine phosphatase 1B promotes mitotic cell death.

O'Donovan DS, MacFhearraigh S, Whitfield J, Swigart LB, Evan GI, Mc Gee MM.

Cell Death Dis. 2013 Jan 24;4:e468. doi: 10.1038/cddis.2012.208.

24.

Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.

Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemelä M, Khanna A, Chan EK, Kähäri VM, Kellokumpu-Lehtinen PL, Sansom OJ, Evan GI, Junttila MR, Ryan KM, Marine JC, Joensuu H, Westermarck J.

Cancer Discov. 2013 Feb;3(2):182-97. doi: 10.1158/2159-8290.CD-12-0292. Epub 2013 Jan 10.

25.

All things to all people.

Littlewood TD, Kreuzaler P, Evan GI.

Cell. 2012 Sep 28;151(1):11-3. doi: 10.1016/j.cell.2012.09.006.

26.

Finding cancer's weakest link.

Sodir NM, Evan GI.

Oncotarget. 2011 Dec;2(12):1307-13. Review.

27.

Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma.

Soucek L, Buggy JJ, Kortlever R, Adimoolam S, Monclús HA, Allende MT, Swigart LB, Evan GI.

Neoplasia. 2011 Nov;13(11):1093-100.

28.

Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology.

Pello OM, De Pizzol M, Mirolo M, Soucek L, Zammataro L, Amabile A, Doni A, Nebuloni M, Swigart LB, Evan GI, Mantovani A, Locati M.

Blood. 2012 Jan 12;119(2):411-21. doi: 10.1182/blood-2011-02-339911. Epub 2011 Nov 8.

29.

Validation of MdmX as a therapeutic target for reactivating p53 in tumors.

Garcia D, Warr MR, Martins CP, Brown Swigart L, Passegué E, Evan GI.

Genes Dev. 2011 Aug 15;25(16):1746-57. doi: 10.1101/gad.16722111.

30.

The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.

Savino M, Annibali D, Carucci N, Favuzzi E, Cole MD, Evan GI, Soucek L, Nasi S.

PLoS One. 2011;6(7):e22284. doi: 10.1371/journal.pone.0022284. Epub 2011 Jul 21.

31.

Endogenous Myc maintains the tumor microenvironment.

Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L.

Genes Dev. 2011 May 1;25(9):907-16. doi: 10.1101/gad.2038411. Epub 2011 Apr 8.

32.

Selective activation of p53-mediated tumour suppression in high-grade tumours.

Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, Brown Swigart L, Pham DM, Seo Y, Evan GI, Martins CP.

Nature. 2010 Nov 25;468(7323):567-71. doi: 10.1038/nature09526.

33.

The ups and downs of Myc biology.

Soucek L, Evan GI.

Curr Opin Genet Dev. 2010 Feb;20(1):91-5. doi: 10.1016/j.gde.2009.11.001. Epub 2009 Dec 3. Review.

34.

Nursing some sense out of Myc.

Sodir NM, Evan GI.

J Biol. 2009 Sep 28;8(8):77. doi: 10.1186/jbiol181.

35.

p53--a Jack of all trades but master of none.

Junttila MR, Evan GI.

Nat Rev Cancer. 2009 Nov;9(11):821-9. doi: 10.1038/nrc2728. Epub 2009 Sep 24. Review.

PMID:
19776747
36.

Acute overexpression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/beta-catenin pathway activation.

Finch AJ, Soucek L, Junttila MR, Swigart LB, Evan GI.

Mol Cell Biol. 2009 Oct;29(19):5306-15. doi: 10.1128/MCB.01745-08. Epub 2009 Jul 27.

37.

MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.

Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimäki A.

J Natl Cancer Inst. 2009 Jun 3;101(11):793-805. doi: 10.1093/jnci/djp103. Epub 2009 May 26.

PMID:
19470954
38.

Absence of caspase-3 protects pancreatic {beta}-cells from c-Myc-induced apoptosis without leading to tumor formation.

Radziszewska A, Schroer SA, Choi D, Tajmir P, Radulovich N, Ho JC, Wang L, Liadis N, Hakem R, Tsao MS, Penn LZ, Evan GI, Woo M.

J Biol Chem. 2009 Apr 17;284(16):10947-56. doi: 10.1074/jbc.M806960200. Epub 2009 Feb 12.

39.

Cellular senescence: hot or what?

Evan GI, d'Adda di Fagagna F.

Curr Opin Genet Dev. 2009 Feb;19(1):25-31. doi: 10.1016/j.gde.2008.11.009. Epub 2009 Jan 30. Review.

PMID:
19181515
40.

Distinct thresholds govern Myc's biological output in vivo.

Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI.

Cancer Cell. 2008 Dec 9;14(6):447-57. doi: 10.1016/j.ccr.2008.10.018.

41.

PTEN deletion and concomitant c-Myc activation do not lead to tumor formation in pancreatic beta cells.

Radziszewska A, Choi D, Nguyen KT, Schroer SA, Tajmir P, Wang L, Suzuki A, Mak TW, Evan GI, Woo M.

J Biol Chem. 2009 Jan 30;284(5):2917-22. doi: 10.1074/jbc.M805183200. Epub 2008 Dec 4.

42.

Modelling Myc inhibition as a cancer therapy.

Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI.

Nature. 2008 Oct 2;455(7213):679-83. doi: 10.1038/nature07260. Epub 2008 Aug 17.

43.

The ever-lengthening arm of p53.

Evan GI.

Cancer Cell. 2008 Aug 12;14(2):108-10. doi: 10.1016/j.ccr.2008.07.012.

44.

The Spy1/RINGO family represents a novel mechanism regulating mammary growth and tumorigenesis.

Golipour A, Myers D, Seagroves T, Murphy D, Evan GI, Donoghue DJ, Moorehead RA, Porter LA.

Cancer Res. 2008 May 15;68(10):3591-600. doi: 10.1158/0008-5472.CAN-07-6453.

45.

Regulated beta-cell regeneration in the adult mouse pancreas.

Cano DA, Rulifson IC, Heiser PW, Swigart LB, Pelengaris S, German M, Evan GI, Bluestone JA, Hebrok M.

Diabetes. 2008 Apr;57(4):958-66. Epub 2007 Dec 14.

46.

Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim.

Abayasiriwardana KS, Barbone D, Kim KU, Vivo C, Lee KK, Dansen TB, Hunt AE, Evan GI, Broaddus VC.

Mol Cancer Ther. 2007 Oct;6(10):2766-76.

47.

Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation.

Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindström MS, Bhat KP, Godfrey VL, Evan GI, Zhang Y.

Cancer Cell. 2007 Oct;12(4):355-66.

48.

Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors.

Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI.

Nat Med. 2007 Oct;13(10):1211-8. Epub 2007 Sep 30.

PMID:
17906636
49.

Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma.

Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB.

J Clin Invest. 2007 Feb;117(2):326-36. Epub 2007 Jan 18.

50.

Modeling the therapeutic efficacy of p53 restoration in tumors.

Martins CP, Brown-Swigart L, Evan GI.

Cell. 2006 Dec 29;127(7):1323-34. Epub 2006 Dec 21.

Supplemental Content

Support Center